



Idera Pharmaceuticals to Present at Wachovia 2008 Healthcare Conference

January 24, 2008 1:02 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2008--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today announced that it will present at the Wachovia 2008 Healthcare Conference. The Company will discuss its TLR-targeted drug discovery and development programs and provide a general corporate update. The presentation will be delivered on Wednesday, January 30, 2008 at 1:30 p.m. (EST) at the Langham Hotel in Boston, MA.

The presentation will be available via live audio webcast on the Company's website at www.iderapharma.com. Archived replays will also be located on the Company's site following the event.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific TLRs, which are a family of immune system receptors present in immune system cells that direct the immune system to respond to potential disease threats. Our pioneering DNA chemistry expertise enables us to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. Our lead TLR9 agonist, IMO-2125, is currently in a Phase 1 trial for the treatment of hepatitis C virus infection. We have also created novel DNA-based compounds that have been shown to act as antagonists to TLRs 7 and 9 in preclinical studies. Idera is collaborating with Novartis International Pharmaceutical, Ltd. for the discovery, development, and commercialization of TLR9 agonists for the treatment of asthma and allergy indications. Idera is also collaborating with Merck & Co., Inc. for the use of Idera's TLR7, 8 and 9 agonists in combination with Merck & Co.'s therapeutic and prophylactic vaccines in the areas of oncology, infectious diseases, and Alzheimer's disease. In addition, Idera is collaborating with Merck KGaA for the research, development and commercialization of Idera's most advanced clinical candidate, IMO-2055, as well as IMO-2125 and other TLR9 agonists for the treatment of cancer. Merck & Co. of the U.S. is not related to Merck KGaA of Germany. For more information, please visit www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed;; whether the Company's collaborations with Novartis, Merck & Co., and Merck KGaA will be successful; whether Idera's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q filed on November 13, 2007, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

CONTACT:

Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluthje@iderapharma.com

or

MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com

SOURCE: Idera Pharmaceuticals, Inc.